9 Mar 2020 – EyRIS is pleased to announce that SELENA+, a deep learning AI system designed to detect diabetic retinopathy, glaucoma-suspect and age-related macular degeneration, jointly invented by clinicians and scientists from Singapore Eye Research Institute (SERI) and NUS School of Computing has received CE Marking certification. EyRIS is a start-up company established to commercialise SELENA+, which was trained and validated with an image dictionary of with over half a million images.

SELENA+ was cited recently by Deputy Prime Minister Mr Heng Swee Keat as one of key healthcare projects in Singapore’s National AI Strategy.

On 5 March 2020, during the MOH Committee of Supply debate, SELENA+ was also cited as an example of an innovative technology to tackle healthcare challenges by Singapore’s Minister of Health Mr Gan Kim Yong, “One example we are already deploying is the Singapore Eye Lesion Analyser Plus (SELENA+). This is a deep-learning artificial intelligence software system which can detect three major eye conditions: diabetic eye disease, glaucoma and age-related macular degeneration. SELENA+ highlights areas with potential vision threatening eye disease and refers abnormal cases to human graders, allowing them to focus on the more complex cases. SELENA+ has proven to be more efficient in delivering fast and accurate results.”

The certification mark indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area (EEA). It is an important milestone for EyRIS as it provides access to aside from the EEA, several key markets around the world including Middle East, Africa, and Australia. SELENA+ has now both Health Science Authority (HSA) certification from Singapore and CE Mark.

Comments are closed.